# Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

> **NCT04791384** · PHASE1,PHASE2 · TERMINATED · sponsor: **Criterium, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Elacestrant

## Key facts

- **NCT ID:** NCT04791384
- **Lead sponsor:** Criterium, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-21
- **Primary completion:** 2024-09-16
- **Final completion:** 2024-09-17
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study was terminated due to delayed recruitment.
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04791384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04791384, "Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT04791384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*